angiotensin ii has been researched along with 2019 Novel Coronavirus Disease in 136 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 136 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arthur, JM; Boehme, KW; Forrest, JC; Harville, TO; Herzog, C; Kennedy, JL; Liu, J; Owens, S | 1 |
| Espejel-Nuñez, A; Espino-Y-Sosa, S; Estrada-Gutierrez, G; Guzman-Guzman, IP; Hernandez-Pacheco, JA; Juarez-Reyes, A; Lopez-Ceh, FE; Martinez-Portilla, RJ; Mateu-Rogell, P; Poon, LC; Rojas-Zepeda, L; Solis-Paredes, JM; Torres-Torres, J; Villafan-Bernal, JR | 1 |
| Akdeniz, YS; Biberoğlu, S; Bolayırlı, İM; Börekçi, Ş; Çakmak, F; İkizceli, İ; İpekci, A; Kanbakan, A; Konukoğlu, D; Özkan, S; Ürkmez, S | 1 |
| Boytsova, EB; Lopatina, OL; Morgun, AV; Salmin, VV; Salmina, AB | 1 |
| An, J; Asaka, MN; Chan, CC; Chan, JF; Fujino, Y; Hoshizaki, M; Imai, M; Imai, Y; Kamada, H; Kamitani, W; Kawaoka, Y; Kiso, M; Kuba, K; Maeda, K; Minato, T; Motoyama, S; Nagata, S; Niiyama, M; Nirasawa, S; Nukiwa, R; Penninger, JM; Poon, VK; Saku, A; Takahashi, S; Uda, A; Utsumi, D; Yamaguchi, T; Yasuhara, A; Yasutomi, Y; Yuen, KY | 1 |
| Colombo, D; Del Nonno, F; Gheblawi, M; Kassiri, Z; MacIntyre, E; Munan, M; Nikhanj, A; O'Neil, C; Oudit, GY; Poglitsch, M; Sligl, W; Wang, K | 1 |
| Javanmardi, K; Soltani Hekmat, A | 1 |
| Bartosova, L; Galis, P; Goncalvesova, E; Klimas, J; Paulis, L; Rajtik, T | 1 |
| Castiglione, GM; Duh, EJ; Hung, CF; Neiman, Z; Xu, Z; Zhou, L | 1 |
| Hu, K; Ling, S; Liu, J; Xu, JW; Zhang, Q | 1 |
| Chen, X; Gao, H; Li, F; Sun, Q; Wang, J; Wu, H; Xu, J; Yang, R; Yuan, S | 1 |
| Bernardi, S; Candido, R; Cortello, T; Fabris, B; Toffoli, B; Tommasi, E; Tonon, F | 1 |
| Bethea, JR; Drummer, C; Hu, W; Jiang, X; Kunapuli, SP; Lu, Y; Saaoud, F; Shao, Y; Sun, J; Sun, Y; Vazquez-Padron, RI; Wang, H; Wu, S; Xu, K; Yang, X; Yu, J | 1 |
| Chen, Y; Feng, L; He, Y; Huang, B; Huang, X; Peng, J; Shi, J; Wang, L | 1 |
| Brini, M; Calì, T; Caputo, I; Caroccia, B; Frasson, I; Morpurgo, M; Poggio, E; Richter, SN; Rossi, GP; Seccia, TM; Zamberlan, S | 1 |
| Lampa, E; Loader, J; Sundström, J; Taylor, FC | 1 |
| Brizzio, A; Cela, EM; Corradi, GR; Espeche, WG; Gironacci, MM; Gonzales Maglio, DH; Nuñez, M; Pérez Duhalde, JI; Salazar, MR; Silva, MG | 1 |
| Chen, C; Jiang, X; Jiang, Y; Jiang, Z; Liu, G; Mao, L; Qin, X; Qiu, F; Qiu, J; Zhang, J; Zhang, L; Zhang, Y; Zou, Z | 1 |
| Baranowska-Kuczko, M; Krzyżewska, A; Malinowska, B; Mińczuk, K; Schlicker, E | 1 |
| Baglieri, C; Capelli, C; Casolo, A; Conti, E; Gattoni, C; Girardi, M; Jurkiewicz, A; Jurkiewicz, NH; Musial, DC; Nuccio, S; Rocha, K; Souza Bomfim, GH | 1 |
| Apiñaniz, A; Argaluza, J; Bermúdez-Ampudia, C; Cobos-Campos, R; Cordero, J; García, S; Orruño, E; Parraza, N; Sáez de Lafuente, A | 1 |
| André, S; Boulle, C; Cezar, R; Claret, PG; Corbeau, P; Duvnjak, S; Estaquier, J; Gimenez, S; Kundura, L; Lefrant, JY; Lin, YL; Loubet, P; Lozano, C; Mettling, C; Muller, L; Pasero, P; Portalès, P; Reynes, J; Roger, C; Sotto, A; Tran, TA; Vincent, T; Younas, M | 1 |
| An, J; Hoshizaki, M; Imai, Y; Kuba, K; Minato, T; Nirasawa, S; Penninger, JM; Takahashi, S; Yamaguchi, T | 1 |
| Attwell, D; Freitas, F; Hirunpattarasilp, C; Huo, J; James, G; Kittler, JT; Kwanthongdee, J; McCoy, LE; Owens, RJ; Sethi, H | 1 |
| Alamri, HS; Alamro, AA; Alghamdi, AA; Alghamdi, J; Alhendi, Y; Almutlaq, M; Alroqi, F; Barhoumi, T; Mansour, FA | 1 |
| Alborino, E; Atalay, S; Bellomo, R; Çakmak, G; Carà, GA; de Paula, MS; Donmez, MB; Fonseca, M; Landoni, G; Pasin, L; Schimmel, M; Yilmaz, B; Zarbock, A | 1 |
| Calò, LA; Nalesso, F; Stefanelli, LF | 1 |
| Barthelemy, J; Bogard, G; Briand, F; Chabrat, A; Deruyter, L; Domenig, O; Heumel, S; Hoffmann, E; Infanti, F; Machelart, A; Nogueiras, R; Pinet, F; Prévot, V; Richard, V; Robil, C; Sencio, V; Sulpice, T; Trottein, F; Wolowczuk, I | 1 |
| Adamaki, M; Cherneva, R; Dabchev, K; Hadjiolova, R; Kadiyska, T; Mitev, V; Spandidos, DA; Stoynev, N; Tourtourikov, I; Zoumpourlis, V | 1 |
| Jamzad, S; Ketabchi, F | 1 |
| Fiorillo, MT; Mattorre, B; Paladini, F; Paldino, G; Sorrentino, R; Tedeschi, V | 1 |
| Briquez, PS; Changrob, S; Dugan, HL; Gajewski, TF; Hubbell, JA; Pyzer, AR; Rouhani, SJ; Sperling, AI; Stamper, CT; Swartz, MA; Trujillo, J; Wilson, PC; Yu, J | 1 |
| Chen, F; Hou, Z; Liu, G; Lu, Y; Lv, X; Xing, C; Zhang, C; Zhang, D | 1 |
| Ballmann, R; Barbieri, SS; Bertoglio, F; Dübel, S; Heine, PA; Hust, M; Jaron, M; Kempter, S; Köster, RW; Lak, A; Lehky, M; Schneider, KT; Schubert, M; van den Heuvel, J; Wenzel, EV; Zarà, M; Zaydowicz, CN | 1 |
| Aw, TC; Papadopoulos, KI; Papadopoulou, A | 2 |
| Aberle, JH; Abrahamowicz, A; Binder, C; Bonderman, D; Domenig, O; Eskandary, F; Gorkiewicz, G; Hecking, M; Heinzel, A; Hödlmoser, S; Jilma, B; Karolyi, M; König, F; Krenn, K; Krenn, S; Mayfurth, H; Mußnig, S; Oberbauer, R; Poglitsch, M; Puchhammer-Stöckl, E; Rathkolb, V; Reindl-Schwaighofer, R; Rumpf, B; Schmölz, L; Schörgenhofer, C; Strassl, R; Tinhof, V; Traugott, MT; Ullrich, R; Wenisch, C; Zoufaly, A | 1 |
| Bustamante, J; Castellar-Lopez, J; Chang, A; Fernanda Pérez, M; Luna, P; Mendoza-Torres, E; Montoya, Y; Rosales-Rada, W | 1 |
| Balasubramanian, N; James, TD; Marcinkiewcz, CA; Reinhardt, J; Selvakumar, GP | 1 |
| Chen, C; Ding, H; Gao, J; Liu, Y; Qian, J; Quarm, AK; Sun, J; Sun, T; Xi, S; Zhang, D | 1 |
| Aguiar, RS; Andrade, LM; Antonio, LM; Antunes, MM; Bittar, C; Brener, MRG; Brieño-Enríquez, M; Caldeira-Brant, AL; Campolina-Silva, GH; Campos, GRF; Cassali, GD; Chiarini-Garcia, H; Costa, GMJ; Costa, VV; da Fonseca, FG; de Souza, FG; Figueiredo, AFA; Furtado, MH; Furtado, TP; Guimaraes, YL; Kangussu, LM; Kauffmann-Zeh, A; Lacerda, SMSN; Martinez-Marchal, A; Martins, EMN; Mendes, BP; Menezes, GB; Nogueira, ML; Orwig, KE; Pacifico, LGG; Procópio, MS; Rahal, P; Souza, FR; Versiani, AF; Wnuk, NT | 1 |
| Fernandez-Llimos, F; Fresco, P; Gonçalves, J; Santos, CD | 1 |
| Apodaca, KD; Barksdale, A; Bernard, GR; Bistran-Hall, AJ; Boyle, K; Brown, SM; Busse, LW; Chen, P; Collins, SP; de Wit, M; DeClercq, J; Douglas, IS; Duggal, A; Files, DC; Gentile, N; Gibbs, KW; Ginde, AA; Hager, DN; Harkins, M; Hudock, KM; Iovine, N; Javaheri, A; Joly, MM; Khan, A; Lanspa, M; Lavieri, R; Levitt, J; Merck, LH; Moskowitz, A; Orr, M; Pulley, J; Puskarich, M; Rice, TW; Rosenberg, Y; Safdar, B; Schildcrout, JS; Schrager, H; Self, WH; Semler, MW; Shotwell, MS; Sturek, JM; Tiffany, B; Troendle, J; Venkateshaiah, L; Vonderhaar, D; Wang, L | 1 |
| Antonelli, J; Bruce, A; Dhaliwal, K; Edwards, C; Finlayson, K; Gaughan, E; Husain, F; Kerai, S; Li, F; Malhotra, V; Mills, B; Moore, A; Pandey, NB; Quinn, TM; Saxena, KN; Shankar-Hari, M; Singh, V; Wadhwa, B | 1 |
| Jin, F; Li, L; Liu, Y; Meng, W; Qi, F; Sun, Q; Yang, B; Zhang, Z | 1 |
| Geng, M; Jiang, X; Liu, W; Tan, Z; Xin, Y | 1 |
| Aragno, M; Sansoè, G | 1 |
| Ando, Y; Chiba, Y; Hanazaki, M; Ishizaka, S; Ito, M; Sakai, H; Suto, W; Takenoya, F; Torizuka, A; Ueda, C; Watanabe, C; Yamashita, M | 1 |
| Avan, A; Froutagh, MHS; Ghotbani, F; Jamshidi, R; Lotfian, E; Mahaki, H; Mahmoodian, R; Nobari, S; Saki, S; Sheykhhasan, M; Tanzadehpanah, H | 1 |
| Haas, K; Hong, RJ; Kim, CS; Meyers, WM; Sin, WC | 1 |
| Kato, CD; Kitibwa, A; Matovu, E; Namayanja, M; Niyonzima, N; Nsubuga, J; Othieno, E; Ssebugere, P; Tumwine, AA | 1 |
| Chen, L; Feng, C; Huang, F; Jiang, C; Li, J; Liu, L; Liu, Y; Peng, L; Qin, Y; Tan, S; Wang, F; Wang, L; Wang, Z; Xu, J; Yang, Y; Yin, L; Yuan, J; Zhang, C; Zhang, Z; Zhao, D; Zhou, C | 1 |
| Su, GH; Sun, ML; Sun, YP; Yang, JM | 1 |
| Chow, JH; Mazzeffi, MA; McCurdy, MT | 2 |
| Brown, TS; Cohen, JB; Hanff, TC; Harhay, MO; Mohareb, AM | 1 |
| Bavishi, C; Maddox, TM; Messerli, FH | 1 |
| Busse, LW; Chow, JH; Khanna, AK; McCurdy, MT | 1 |
| Battistoni, A; Volpe, M | 1 |
| Lundström, A; Sandén, P | 1 |
| Azad, N; Bartlett, B; Chowdhury, A; Das, S; Jain, N; Khan, SA; Kolar, GJ; Subla, MR; Taji, J; Wang, H; Wieruszewski, PM | 1 |
| Barakat, AG; Bezdicek, T; Chipman, JG; Ingraham, NE; Puskarich, MA; Reilkoff, R; Schacker, T; Tignanelli, CJ | 1 |
| Kai, H; Kai, M | 1 |
| Alfano, G; Cappelli, G; Ferrari, A; Fontana, F; Guaraldi, G; Magistroni, R; Mussini, C | 1 |
| Fei, C; Hao-Ran, C; Hao-Ran, W; Jing, Y; Run-Qian, L; Ya-Bin, L; Yang, G | 1 |
| Gonzalez, I; Morales, MA; Rojas, A | 1 |
| Soleimani, M | 1 |
| Kwaan, HC | 1 |
| Shete, A | 1 |
| Lefkowitz, RJ; Manglik, A; Rockman, HA; Wingler, LM | 1 |
| Bellomo, R; Beretta, L; Landoni, G; Morselli, F; Serpa Neto, A; Zangrillo, A | 1 |
| Chevassut, TJ; Milne, KM; Sturrock, BR | 1 |
| Ferreira, JA; Jankowski, CA; Mcmanus, J; Searcy, R | 1 |
| Montijn, R; Offringa, A; Paul, M; Pinto, YM; Pinto-Sietsma, SJ; Singh, S | 1 |
| Carrer, A; Casati, M; Contro, E; Gambacorti-Passerini, C; Giardini, V; Vergani, P | 1 |
| Mao, XY; Peng, W; Wu, ML; Yin, XX; Zheng, XR | 1 |
| Lu, TS; Tseng, YH; Yang, RC | 1 |
| Verdiner, RE | 1 |
| Speth, RC | 1 |
| Hu, R; Ren, W; Wu, Z; Yu, A; Zhang, C; Zhou, X | 1 |
| Gadbail, A; Gondivkar, S; Gopalakrishnan, D; Patil, S; Sarode, GS; Sarode, SC | 1 |
| Moita, LF; Póvoa, P; Tralhão, A | 1 |
| Hrenak, J; Simko, F; Zorad, S | 1 |
| Danser, AHJ; de Maat, S; de Mast, Q; Maas, C; van de Veerdonk, FL | 1 |
| Chávez-Alderete, J; Loza-Mejía, MA; Maldonado, V | 1 |
| Beer, JH; Saeedi Saravi, SS | 1 |
| Berthelot, JM; Drouet, L; Lioté, F | 1 |
| Delpino, MV; Quarleri, J | 1 |
| Bendjelid, K | 1 |
| Lazartigues, E; Mauvais-Jarvis, F; Qadir, MMF | 1 |
| Jorge-Aarón, RM; Rosa-Ester, MP | 1 |
| Boulton, ME; Grant, MB; Li Calzi, S; Obukhov, AG; Oudit, GY; Prasad, R; Raizada, MK; Stevens, BR | 1 |
| Kakar, SS; Straughn, AR | 1 |
| Batlle, D; Kaplan, N; Lavker, RM; Lu, K; Peng, H; Wang, J; Wysocki, J; Yang, W | 1 |
| Cao, JJ; Zheng, H | 1 |
| Gan, R; Georgius, P; Henshaw, DJE; Noble, EP; Rosoman, NP; Sommerfeld, N | 1 |
| Sunavala-Dossabhoy, G | 1 |
| Caruso-Neves, C; Carvalho, VF; E Silva, PMR; Martins, MA; Peruchetti, DB; Pinheiro, AAS; Rocco, PRM; Schmaier, AH; Silva-Aguiar, RP | 1 |
| Bobeck, KA; Brown, TE; Clark, PA; Holtzclaw, AW | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Angus, PW; Burrell, LM; Casey, S; Grace, JA | 1 |
| Eriksson, LI; Fagerlund, MJ; Jalde, FC; Lundberg, J; Oldner, A; Rysz, S | 1 |
| Chopra, T; Draghici, S; Elahi, M; Esber, Z; Gabali, A; Hanoudi, S; Samavati, L; Sano, D; Taha, M | 1 |
| Seltzer, S | 1 |
| Hooper, NM; Lambert, DW; Turner, AJ | 1 |
| Al Husami, W; Alkhatib Tamimi, F; Ganatra, S; Liu, Y; Ofosu-Barko, K; Resnic, F; Shah, SP | 1 |
| Baldus, N; Bode, C; Busch, HJ; Duerschmied, D; Goller, I; Hofmann, M; Jeserich, M; Kern, W; Lother, A; Pollmeier, L; Rieder, M; Schmid, B; Wirth, L | 1 |
| Kaesemeyer, W; Suvorava, T | 1 |
| Belloni, L; Fama, A; Giuri, PG; Negro, A; Penna, D; Zerbini, A | 1 |
| Aberle, JH; Bergthaler, A; Grieb, A; Haider, D; Hoepler, W; Laferl, H; Mirazimi, A; Montserrat, N; Neuhold, S; Pawelka, E; Penninger, JM; Poglitsch, M; Puchhammer-Stoeckl, E; Seitz, T; Slutsky, AS; Stiasny, K; Traugott, M; Wenisch, C; Zhang, H; Zoufaly, A | 1 |
| Ichikawa, N; Okamoto, H | 1 |
| Acosta-Ampudia, Y; Anaya, JM; Monsalve, DM; Ramírez-Santana, C; Rojas, M | 1 |
| Rakugi, H; Takeshita, H; Yamamoto, K | 1 |
| Cohen, JB; Edmonston, DL; South, AM; Sparks, MA | 1 |
| Balestrieri, A; Barcellona, D; Caocci, G; Castagnola, M; Cau, R; Coghe, F; Coni, P; D'Andrea, F; Faa, G; Fanni, D; Gerosa, C; La Nasa, G; Ledda, F; Marongiu, F; Orru, G; Piras, M; Ronchi, A; Saba, L; Suri, JS | 1 |
| Chappell, MC; Gwathmey, TM; Pirro, NT; South, AM | 1 |
| Krishnan, S; Li, J; Mohandas, R; Raizada, MK; Richards, EM; Sharma, RK | 1 |
| Ahmed, A; Hasan, M; Rahman, MM | 1 |
| Filipeanu, CM; Lazartigues, E; Ogunlade, BO | 1 |
| Avanoglu Guler, A; Aygencel, G; Aysert Yıldız, P; Dizbay, M; Erbaş, G; Gulbahar, O; Guzel Tunçcan, O; Hızel, K; Özger, HS; Öztürk, MA; Tombul, N; Tufan, A | 1 |
| Apostolopoulos, V; Kelaidonis, K; Matsoukas, J; Mavromoustakos, T; Moore, G; Moschovou, K; Zulli, A | 1 |
| Bagatini, PB; Mestriner, RG; Neves, LT; Neves, PFR; Paz, LV; Rasia-Filho, AA; Timmers, LFSM; Wieck, A; Xavier, LL | 1 |
| Bernasconi, L; Conen, A; Domenig, O; Gregoriano, C; Haubitz, S; Koch, D; Kutz, A; Mueller, B; Schuetz, P | 1 |
| Akasaka, H; Fujimoto, T; Hongyo, K; Huang, Y; Nakagami, F; Nakajima, T; Nozato, Y; Rakugi, H; Sugimoto, K; Takami, Y; Takeshita, H; Takeya, Y; Wang, C; Wang, Y; Yamamoto, K; Yokoyama, S | 1 |
| Akdeniz, YS; Balkan, II; Biberoglu, S; Bolayirli, IM; Cakmak, F; Dumanli, GY; Ikizceli, I; Ipekci, A; Konukoglu, D; Ozkan, S | 1 |
| Alcaro, F; Antonelli, M; Cutuli, SL; Eleuteri, D; Montini, L; Rossi, C | 1 |
| Chernyak, BV; Grebenchikov, OA; Popova, EN; Prikhodko, AS; Zinovkin, RA; Zinovkina, LA | 1 |
| Ghasemnejad-Berenji, M; Khezri, MR; Yousefi, K | 1 |
| Bozza, WP; Dean, AQ; Luo, S; Nalli, A; Twomey, JD; Zhang, B | 1 |
| Abdula, G; Al-Saadi, J; Campoccia Jalde, F; Eriksson, H; Farm, M; Granberg, T; Jonsson Fagerlund, M; Klein, M; Lundberg, J; Nyrén, S; Ouellette, R; Plattén, M; Rysz, S; Sjöström, A; Vargas-Paris, R | 1 |
| Pawlikowski, M; Winczyk, K | 1 |
| Ahmad, T; Al Mutair, A; Al-Ahmed, SH; Alhumaid, S; Bilal, M; Dhama, K; Dhawan, M; Fawzy, M; Hasan, A; Khan, A; Muhammad, J; Rabaan, AA; Sah, R; Shrestha, DB; Sule, AA; Tirupathi, R; Tiwari, R | 1 |
| Gando, S; Wada, T | 1 |
| Brouqui, P; Devaux, CA; La Scola, B; Lagier, JC; Meddeb, L; Mege, JL; Melenotte, C; Million, M; Osman, IO; Parola, P; Raoult, D; Stein, A | 1 |
| Apostolopoulos, V; Gadanec, LK; Kelaidonis, K; Matsoukas, JM; Moore, GJ; Pires, JM; Zulli, A | 1 |
| Ghasemnejad-Berenji, M; Khezri, MR | 1 |
46 review(s) available for angiotensin ii and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Molecular Mechanisms of Proteins - Targets for SARS-CoV-2 (Review).
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Astrocytes; Basigin; Brain; COVID-19; Humans; Peptide Fragments; SARS-CoV-2; Serine Endopeptidases | 2021 |
Alamandine: Potential Protective Effects in SARS-CoV-2 Patients.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Oligopeptides; Peptide Fragments; Renin-Angiotensin System | 2021 |
Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Humans; Hypoxia; Lung; Myocardial Infarction; Peptide Fragments; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19).
Topics: Angiotensin II; Animals; COVID-19; Extracellular Traps; Humans; Neutrophils; Peptidyl-Dipeptidase A; Phenotype; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment.
Topics: Adult; Angiotensin II; Blood Pressure; Cognitive Dysfunction; COVID-19; Humans; Hypertension; Middle Aged; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2022 |
Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Humans; Hypertension; Renin; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance.
Topics: Angiotensin II; Cannabinoids; COVID-19; Endocannabinoids; Humans; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cannabinoid; Renin; Renin-Angiotensin System | 2022 |
Topics: Angiotensin II; COVID-19; Humans; Renin-Angiotensin System; SARS-CoV-2; Sepsis; Vasoconstrictor Agents | 2022 |
Role of endothelial dysfunction in the severity of COVID‑19 infection (Review).
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Collagen; COVID-19; Endothelial Cells; Endothelins; Humans; Interleukin-6; Interleukin-8; Nitric Oxide; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Receptors, Angiotensin; Tumor Necrosis Factor-alpha; Vascular Diseases | 2022 |
Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Bradykinin; COVID-19; Humans; Peptidyl-Dipeptidase A; Prostaglandin-Endoperoxide Synthases; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
The emerging multifunctional roles of ERAP1, ERAP2 and IRAP between antigen processing and renin-angiotensin system modulation.
Topics: Aminopeptidases; Angiotensin II; Antigen Presentation; COVID-19; Humans; Insulin; Minor Histocompatibility Antigens; Renin-Angiotensin System; Zinc | 2022 |
A protective erythropoietin evolutionary landscape, NLRP3 inflammasome regulation, and multisystem inflammatory syndrome in children.
Topics: Aldosterone; Angiotensin II; Child; COVID-19; Endothelial Cells; Erythropoietin; Humans; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; SARS-CoV-2 | 2023 |
Potential of Angiotensin-(1-7) in COVID-19 Treatment.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Pandemics; Peptidyl-Dipeptidase A; Renin-Angiotensin System; SARS-CoV-2 | 2023 |
Beauty and the beast: host microRNA-155 versus SARS-CoV-2.
Topics: Angiotensin II; Antiviral Agents; COVID-19; Humans; MicroRNAs; Peptidyl-Dipeptidase A; SARS-CoV-2 | 2023 |
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Inflammation; Peptidyl-Dipeptidase A; Renin-Angiotensin System; SARS-CoV-2 | 2023 |
Impact of the gut microbiota on angiotensin Ⅱ-related disorders and its mechanisms.
Topics: Angiotensin II; COVID-19; Diabetes Mellitus, Type 2; Disease Progression; Gastrointestinal Microbiome; Humans; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 2023 |
New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; COVID-19; Humans; Hypertension; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Peptidyl-Dipeptidase A; Renin-Angiotensin System; SARS-CoV-2 | 2023 |
Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Cytokines; Endothelial Cells; Humans; Hypertension; Peripheral Vascular Diseases; SARS-CoV-2 | 2023 |
Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Topics: Acute Lung Injury; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Potential influence of COVID-19/ACE2 on the female reproductive system.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Gene Expression Regulation; Genitalia, Female; Host-Pathogen Interactions; Humans; Pandemics; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Protein Binding; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae.
Topics: Angiotensin II; Animals; Antifibrinolytic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Models, Animal; Fibrinolysin; Fibrinolysis; Humans; Lung; Multiple Organ Failure; Pandemics; Plasminogen Activator Inhibitor 1; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Thrombophilia; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2020 |
β-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; beta-Arrestins; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
The renin-angiotensin system - a therapeutic target in COVID-19?
Topics: Amides; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Fumarates; Humans; Lung Injury; Mice; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Virus Internalization | 2020 |
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Endocytosis; Host-Pathogen Interactions; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Virus Internalization | 2020 |
Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Humans; Models, Biological; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Betacoronavirus; Bradykinin; Chick Embryo; Coronavirus Infections; COVID-19; Disease Models, Animal; Humans; Kininogens; Mice; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pulmonary Edema; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?
Topics: Angiotensin II; Animals; Aspirin; Blood Coagulation Disorders; Coronavirus Infections; COVID-19; Dipyridamole; Humans; Immunoglobulins, Intravenous; Interferons; Membrane Proteins; Mice; Mucocutaneous Lymph Node Syndrome; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Signal Transduction; Thrombosis | 2020 |
Endocrine Significance of SARS-CoV-2's Reliance on ACE2.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Brain; Coronavirus Infections; COVID-19; Diabetes Complications; Endocrine System Diseases; Gene Expression; Humans; Hypogonadism; Mice; Pandemics; Peptidyl-Dipeptidase A; Pituitary Diseases; Pneumonia, Viral; Rats; Renin-Angiotensin System; SARS-CoV-2; Serine Endopeptidases; Thyroid Diseases | 2020 |
Withaferin A: a potential therapeutic agent against COVID-19 infection.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Cachexia; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Mice; Ovarian Neoplasms; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Withanolides; Xenograft Model Antitumor Assays | 2020 |
Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Lung Injury; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Polymorphism, Genetic; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hypertension; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; Risk Factors; SARS-CoV-2 | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Targeting the Vascular Endothelium in the Treatment of COVID-19.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Delivery Systems; Endothelium, Vascular; Humans | 2021 |
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Humans; Muscle, Skeletal; Peptide Fragments; SARS-CoV-2 | 2020 |
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Topics: Acute Lung Injury; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; COVID-19; Humans; Hypertension; JNK Mitogen-Activated Protein Kinases; Lung; MAP Kinase Signaling System; Peptide Fragments; Protective Factors; Receptors, Coronavirus; Renin-Angiotensin System; Risk Factors; SARS-CoV-2; Up-Regulation | 2020 |
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Atrial Fibrillation; Blood Coagulation; Capillary Permeability; Cardiomyopathies; COVID-19; Cytokine Release Syndrome; Cytokines; Endothelium, Vascular; Fibroblasts; Fibrosis; Humans; Liver Cirrhosis; Myocarditis; Receptors, Coronavirus; Renin-Angiotensin System; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Thrombosis; Virus Internalization | 2020 |
Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Heart Diseases; Humans; Kidney Diseases; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.
Topics: ADAM17 Protein; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Comorbidity; COVID-19; Humans; Peptide Fragments; SARS-CoV-2 | 2021 |
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; COVID-19; COVID-19 Drug Treatment; Humans; Hypertension; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
Does Angiotensin II Peak in Response to SARS-CoV-2?
Topics: Angiotensin II; COVID-19; Host-Pathogen Interactions; Humans; Immunity; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
COVID-19 and Oxidative Stress.
Topics: Angiotensin II; Antioxidants; COVID-19; COVID-19 Drug Treatment; Cytokines; Endothelium; Humans; Immunity, Innate; Oxidative Stress; Reactive Oxygen Species; SARS-CoV-2 | 2020 |
The fight against COVID-19: Striking a balance in the renin-angiotensin system.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; COVID-19 Drug Treatment; Humans; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
Endocrine and metabolic aspects of COVID-19.
Topics: Aging; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Diabetes Mellitus; Humans; Melatonin; Obesity; Renin-Angiotensin System | 2021 |
Immunopathogenesis and immunobiology of SARS-CoV-2.
Topics: Adaptive Immunity; Angiotensin II; Angiotensin-Converting Enzyme 2; Antibody-Dependent Enhancement; B-Lymphocytes; COVID-19; Humans; Immunity, Cellular; Immunity, Innate; Lung; SARS-CoV-2; Serine Endopeptidases; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Virus Attachment | 2021 |
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Topics: Angiotensin II; Animals; Blood Coagulation Disorders; COVID-19; Cytokines; Factor XIIa; Humans; Inflammation; Inflammation Mediators; SARS-CoV-2 | 2021 |
2 trial(s) available for angiotensin ii and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi.
Topics: Aldosterone; Angiotensin II; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Randomized Controlled Trials as Topic; SARS-CoV-2; Spironolactone; Treatment Outcome; von Willebrand Factor | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
89 other study(ies) available for angiotensin ii and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Development of ACE2 autoantibodies after SARS-CoV-2 infection.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Autoantibodies; COVID-19; Female; Humans; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Novel Ratio Soluble Fms-like Tyrosine Kinase-1/Angiotensin-II (sFlt-1/ANG-II) in Pregnant Women Is Associated with Critical Illness in COVID-19.
Topics: Adult; Angiotensin II; Biomarkers; Cohort Studies; COVID-19; Critical Illness; Female; Humans; Mexico; Placenta; Pre-Eclampsia; Pregnancy; Pregnant Women; Prospective Studies; SARS-CoV-2; Vascular Endothelial Growth Factor Receptor-1 | 2021 |
Role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Disease-Free Survival; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; SARS-CoV-2; Survival Rate | 2021 |
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Topics: Acute Lung Injury; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Female; Humans; Lung; Lung Injury; Male; Mice; Mice, Transgenic; Pulmonary Edema; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vero Cells; Virus Internalization | 2021 |
Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries.
Topics: ADAM17 Protein; Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Enzyme Activation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peptide Fragments; Prognosis; Prospective Studies; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Renin-Angiotensin System; Respiration, Artificial; Risk; SARS-CoV-2; Treatment Outcome | 2022 |
Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.
Topics: Amino Acids; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Binding Sites; COVID-19; Disease Resistance; Dogs; Epistasis, Genetic; Evolution, Molecular; Gene Frequency; Humans; Hydrolysis; Mice; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Attachment | 2021 |
Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme 2; Case-Control Studies; COVID-19; Diabetes Mellitus, Type 1; Female; Humans; Leukocytes, Mononuclear; Male; Peptidyl-Dipeptidase A; Renin-Angiotensin System; RNA, Viral; SARS-CoV-2 | 2022 |
Aorta in Pathologies May Function as an Immune Organ by Upregulating Secretomes for Immune and Vascular Cell Activation, Differentiation and Trans-Differentiation-Early Secretomes may Serve as Drivers for Trained Immunity.
Topics: Angiotensin II; Aorta; Caspase 1; Cell Differentiation; Cell Transdifferentiation; COVID-19; Cytokines; Endothelial Cells; Humans; Middle East Respiratory Syndrome Coronavirus; NF-E2-Related Factor 2; Renal Insufficiency, Chronic; Secretome | 2022 |
Sars-Cov-2 Spike Protein-Induced Damage of hiPSC-Derived Cardiomyocytes.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Connexin 43; COVID-19; Culture Techniques; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Up-Regulation | 2022 |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Hypertension; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 2022 |
Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein.
Topics: Acute Lung Injury; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Humans; Lipopolysaccharides; Mice; Recombinant Proteins; Respiratory Distress Syndrome; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
Topics: Adult; Angiotensin II; Animals; Athletic Performance; Blood Pressure; COVID-19; Diabetes Mellitus; Humans; Hypertension; Isoproterenol; Male; Muscle Fatigue; Nitric Oxide; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Receptors, Adrenergic; Running; Soccer; Streptozocin; Wine; Young Adult | 2022 |
Angiotensin II Receptor Blocking Drugs May Increase Severity of Coronavirus Disease 2019 Infection.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; Receptors, Angiotensin; Renin-Angiotensin System | 2022 |
Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19.
Topics: Angiotensin II; Apoptosis; COVID-19; DNA Damage; Humans; Lymphopenia; Reactive Oxygen Species; SARS-CoV-2; T-Lymphocytes | 2022 |
ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury.
Topics: Acute Lung Injury; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; COVID-19; Escherichia coli; Humans; Lung; Mice; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Respiratory Distress Syndrome; SARS-CoV-2; Sepsis | 2022 |
SARS-CoV-2 triggers pericyte-mediated cerebral capillary constriction.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Capillaries; Constriction; COVID-19; Humans; Peptidyl-Dipeptidase A; Pericytes; Protein Binding; Receptors, Virus; SARS-CoV-2 | 2023 |
Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Leukocytes, Mononuclear; Peptidyl-Dipeptidase A; Renin-Angiotensin System; SARS-CoV-2; T-Lymphocytes | 2022 |
Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence.
Topics: Angiotensin II; Bartter Syndrome; COVID-19; Humans | 2022 |
Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Cricetinae; Cytokines; Diet; Disease Models, Animal; Dyslipidemias; Humans; Inflammation; Mesocricetus; Non-alcoholic Fatty Liver Disease; Obesity; SARS-CoV-2 | 2022 |
Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Autoantibodies; Blood Pressure; COVID-19; Epitopes; Humans; Peptidyl-Dipeptidase A; Protein Binding; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus | 2022 |
Changes of ACE2 in different glucose metabolites and its relationship with COVID-19.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; C-Reactive Protein; COVID-19; Diabetes Mellitus, Type 2; Glucose; Humans; Interleukin-6; Peptide Fragments; Prediabetic State | 2022 |
Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Monoclonal; Baculoviridae; COVID-19; Humans; Insecta; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
The systemic renin-angiotensin system in COVID-19.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; COVID-19; Humans; Peptide Hormones; Renin; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
Repeated ethanol exposure and withdrawal alters angiotensin-converting enzyme 2 expression in discrete brain regions: Implications for SARS-CoV-2 neuroinvasion.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Brain; Cathepsin L; COVID-19; Ethanol; Humans; Peptidyl-Dipeptidase A; RNA, Messenger; SARS-CoV-2 | 2023 |
Cyclophilin D-mediated angiotensin II-induced NADPH oxidase 4 activation in endothelial mitochondrial dysfunction that can be rescued by gallic acid.
Topics: Angiotensin II; COVID-19; Gallic Acid; Human Umbilical Vein Endothelial Cells; Humans; Mitochondria; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Peptidyl-Prolyl Isomerase F; Reactive Oxygen Species; Vascular Diseases | 2023 |
High SARS-CoV-2 tropism and activation of immune cells in the testes of non-vaccinated deceased COVID-19 patients.
Topics: Angiotensin II; Animals; Chlorocebus aethiops; COVID-19; Humans; Male; SARS-CoV-2; Testis; Vero Cells; Viral Tropism | 2023 |
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.
Topics: Adult; Angiotensin II; Angiotensins; COVID-19; Female; Humans; Hypoxia; Infusions, Intravenous; Ligands; Male; Middle Aged; Oligopeptides; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Vasodilator Agents | 2023 |
SARS-CoV-2 Spike Protein S1 Exposure Increases Susceptibility to Angiotensin II-Induced Hypertension in Rats by Promoting Central Neuroinflammation and Oxidative Stress.
Topics: Angiotensin II; Animals; Blood Pressure; COVID-19; Cytokines; Humans; Hypertension; Neuroinflammatory Diseases; NF-E2-Related Factor 2; Oxidative Stress; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2023 |
Altered renin-angiotensin system gene expression in airways of antigen-challenged mice: ACE2 downregulation and unexpected increase in angiotensin 1-7.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Asthma; COVID-19; Down-Regulation; Gene Expression; Mice; Ovalbumin; Renin-Angiotensin System; SARS-CoV-2 | 2023 |
A cell-based assay for rapid assessment of ACE2 catalytic function.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Catalysis; COVID-19; Humans; SARS-CoV-2 | 2023 |
Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.
Topics: Angiotensin II; Biomarkers; C-Reactive Protein; COVID-19; Ferritins; Homocysteine; Humans; Interleukin-10; Interleukin-6; Phenotype; Procalcitonin; SARS-CoV-2; Tumor Necrosis Factor-alpha; Uganda | 2023 |
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.
Topics: Adult; Aged; Angiotensin II; Betacoronavirus; Biomarkers; Blood Chemical Analysis; Child; Coronavirus Infections; COVID-19; Humans; Lung Injury; Male; Middle Aged; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index; Viral Load | 2020 |
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Betacoronavirus; Blood Pressure; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Inflammation; Lung; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Prognosis; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock.
Topics: Angiotensin II; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Shock; Vasoconstrictor Agents | 2020 |
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 and the RAAS-a potential role for angiotensin II?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?
Topics: Acute Lung Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hypertension; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Up-Regulation | 2020 |
[ACE2 and coronavirus - a question of balance and dynamics?]
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; Risk Factors; SARS-CoV-2 | 2020 |
Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock.
Topics: Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Male; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Shock, Septic | 2020 |
The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; COVID-19; Down-Regulation; Enzyme Induction; Female; Host-Pathogen Interactions; Humans; Hypertension; Lung; Male; Organ Specificity; Receptors, Coronavirus; Renin-Angiotensin System; Respiratory Distress Syndrome; SARS-CoV-2; Virus Internalization | 2021 |
SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia; Pneumonia, Viral; Receptor for Advanced Glycation End Products; Receptor, Angiotensin, Type 1; SARS-CoV-2 | 2020 |
Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Cathepsins; Cell Death; Coronavirus Infections; COVID-19; Creatinine; Critical Illness; Endosomes; Humans; Hydrogen-Ion Concentration; Incidence; Kidney Tubules, Proximal; Lysosomes; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptors, Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Virus Internalization; Virus Replication | 2020 |
Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; SARS-CoV-2 | 2020 |
Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series.
Topics: Aged; Angiotensin II; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Female; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Shock; Vasoconstrictor Agents; Vasodilation | 2020 |
Why the Use of Angiotensin II May be a Fatal Mistake in COVID-19.
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Placenta Growth Factor; Pneumonia, Viral; SARS-CoV-2; Vascular Endothelial Growth Factor Receptor-1 | 2020 |
Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Blood-Brain Barrier; Brain; Coronavirus Infections; COVID-19; Cytokines; Humans; Inflammation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Vascular Endothelial Growth Factor A | 2020 |
Is Angiotensin II Unopposed a Good Thing?
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
Angiotensin II administration to COVID-19 patients is not advisable.
Topics: Angiotensin II; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral | 2020 |
Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.
Topics: Angiotensin II; Coronavirus Infections; COVID-19; Critical Illness; Humans; Pandemics; Pneumonia, Viral | 2020 |
Oral submucous fibrosis and COVID-19: Perspective on comorbidity.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Down-Regulation; Humans; Mouth; Oral Submucous Fibrosis; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Prevalence; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Potential benefit of angiotensin II in COVID-19 patients: beyond reasonable doubt?
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Virus Internalization | 2020 |
Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.
Topics: Alveolar Epithelial Cells; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Complement Activation; COVID-19; COVID-19 Drug Treatment; Cytokines; Disease Models, Animal; Drug Repositioning; Endothelial Cells; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation; Lymphocyte Subsets; Microcirculation; Oxidative Stress; Pandemics; Pentoxifylline; Rats; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2; Signal Transduction; Venous Thromboembolism | 2020 |
Apelin-potential therapy for COVID-19?
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Apelin; Apelin Receptors; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Mice; Pandemics; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2 | 2020 |
SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.
Topics: Alveolar Epithelial Cells; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus Infections; COVID-19; Host Microbial Interactions; Humans; Lung; Pandemics; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pulmonary Fibrosis; Receptors, Coronavirus; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2; Transforming Growth Factor beta | 2020 |
Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
N-acetylcysteine as a potential treatment for COVID-19.
Topics: Acetylcysteine; Angiotensin II; Antioxidants; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Humans; Oxidative Stress; Pandemics; Pneumonia, Viral; SARS-CoV-2; Virus Internalization | 2020 |
SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Bone Marrow; Coronavirus Infections; COVID-19; Diabetes Mellitus; Humans; Intestinal Mucosa; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2; Severity of Illness Index | 2020 |
The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Cells, Cultured; Chemokines; Cornea; COVID-19; Cytokine Release Syndrome; Disease Models, Animal; Epithelial Cells; Humans; Interleukins; Mice; Mice, Inbred C57BL; Mice, Knockout; SARS-CoV-2; THP-1 Cells; Tumor Necrosis Factor-alpha | 2020 |
COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Anticoagulants; Cardiovascular Diseases; COVID-19; Humans; Hypertension; Models, Theoretical; Peptide Fragments; Renin-Angiotensin System; Respiration; Risk Factors; Venous Thromboembolism; Virus Internalization | 2020 |
Renin-angiotensin II-aldosterone axis in SARS-CoV-2-associated xerostomia.
Topics: Aldosterone; Angiotensin II; COVID-19; Humans; Renin; SARS-CoV-2; Xerostomia | 2022 |
Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.
Topics: Aged, 80 and over; Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Shock; Vasoconstrictor Agents | 2020 |
Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Apoptosis; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Disease Progression; Disease Susceptibility; Humans; Liver Cirrhosis; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Preliminary Data; SARS-CoV-2; Up-Regulation | 2020 |
Treatment with angiotensin II in COVID-19 patients may not be beneficial.
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Platelets and renal failure in the SARS-CoV-2 syndrome.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme 2; Blood Platelets; Comorbidity; COVID-19; Diabetes Mellitus; Female; Fibrin Fibrinogen Degradation Products; Glomerular Filtration Rate; Humans; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pandemics; Receptors, Virus; Renin-Angiotensin System; SARS-CoV-2; Thrombocytopenia; Thrombophilia; Young Adult | 2021 |
Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Lung; SARS-CoV-2; Vascular Diseases | 2020 |
Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2; Vasoconstrictor Agents | 2020 |
Angiotensin II Administration in Patients With COVID-19 Shock.
Topics: Aged; Angiotensin II; Arterial Pressure; COVID-19; Female; Humans; Male; Middle Aged; Retrospective Studies; Shock; Vasoconstrictor Agents | 2021 |
In Response.
Topics: Angiotensin II; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Shock | 2020 |
Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure Determination; COVID-19; Female; Germany; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care; Potassium; Prospective Studies; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
SFLT-1 levels in COVID-19 patients: Association with outcome and thrombosis.
Topics: Angiotensin II; COVID-19; Humans; Placenta Growth Factor; SARS-CoV-2; Thrombosis | 2021 |
Human recombinant soluble ACE2 in severe COVID-19.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Female; Humans; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Recombinant Proteins; SARS-CoV-2 | 2020 |
The pivotal role of the angiotensin-II-NF-κB axis in the development of COVID-19 pathophysiology.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; COVID-19; COVID-19 Drug Treatment; Humans; I-kappa B Proteins; NF-kappa B; Signal Transduction | 2021 |
How Important Is the Assessment of Soluble ACE-2 in COVID-19?
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; SARS-CoV-2 | 2021 |
Concerns on the Specificity of Commercial ELISAs for the Measurement of Angiotensin (1-7) and Angiotensin II in Human Plasma.
Topics: Angiotensin I; Angiotensin II; Chromatography, Agarose; COVID-19; Enzyme-Linked Immunosorbent Assay; Humans; Peptide Fragments; Radioimmunoassay; Reference Standards; Renin-Angiotensin System; SARS-CoV-2; Sensitivity and Specificity; Specimen Handling | 2021 |
Angiotensin Type 1 Receptor-Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Diabetes Mellitus, Type 2; Humans; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Biomarkers; Comorbidity; COVID-19; Female; Humans; Inflammation; Male; Middle Aged; Peptidyl-Dipeptidase A; SARS-CoV-2; Severity of Illness Index | 2021 |
Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; COVID-19; Female; Humans; Male; Middle Aged; Peptide Fragments; Peptidyl-Dipeptidase A; Prospective Studies; Renin; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
Topics: ADAM17 Protein; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Furin; Gene Expression Regulation, Enzymologic; Losartan; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; SARS-CoV-2; Serine Endopeptidases; Vasoconstrictor Agents | 2021 |
Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019.
Topics: Angiotensin II; Biomarkers; COVID-19; Prognosis; Sensitivity and Specificity | 2021 |
Renin-angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report.
Topics: Aged; Aged, 80 and over; Angiotensin I; Angiotensin II; COVID-19; Critical Illness; Female; Humans; Male; Middle Aged; Renin; Renin-Angiotensin System; Respiratory Distress Syndrome | 2021 |
Angiotensin II: A possible target for therapeutic intervention in COVID-19.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; COVID-19; COVID-19 Drug Treatment; Humans; SARS-CoV-2 | 2021 |
COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Female; Humans; Lung; Magnetic Resonance Imaging; Protein Binding; Renin-Angiotensin System; Retrospective Studies; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Swine; Virus Internalization | 2021 |
Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Female; Gene Expression Profiling; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Peptide Fragments; Pilot Projects; Prospective Studies; RNA, Messenger; Virus Shedding | 2021 |
Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; COVID-19; COVID-19 Drug Treatment; Crystallography, X-Ray; Drug Discovery; Humans; Hypertension; Male; Models, Molecular; Rabbits; Receptor, Angiotensin, Type 1; Vasoconstriction | 2021 |
Neurological effects of elevated levels of angiotensin II in COVID-19 patients.
Topics: Alzheimer Disease; Angiotensin II; Angiotensin-Converting Enzyme 2; Blood-Brain Barrier; Cerebral Hemorrhage; COVID-19; Endocytosis; Humans; Permeability; Receptor, Angiotensin, Type 1; SARS-CoV-2 | 2021 |